Orphan Drugs & Rare Diseases 2014: Interview with Gunter Harms Market Access Director

SMi is proud to have Dr. Günter Harms, Market Access & Public Affairs Director at Shire, giving the opening address at this year’s Orphan Drugs and Rare Diseases conference taking place in London on October 20th and 21st 2014.
 
 
Orphan Drugs and Rare Diseases
Orphan Drugs and Rare Diseases
Sept. 29, 2014 - PRLog -- SMi is proud to have Dr. Günter Harms, Market Access & Public Affairs Director at Shire, giving the opening address at this year’s Orphan Drugs and Rare Diseases conference taking place in London on October 20th and 21st 2014. His knowledge and expertise will provide key insight into market access and the challenges faced in the field.

SMi recently caught up with Dr. Günter Harms and here is what he had to say:

Q: What do you believe are the biggest challenges for the pharmaceutical industry regarding Orphan Drugs and Rare Diseases?
A: With the unique complexities of rare diseases and national differences in patient access it really requires a lot of dialogue between stakeholders. General trends such as the evolving HTA processes also impact orphan drugs and require new approaches and also increased involvement of the patient and patient representatives.

Q: What is the future for Orphan Drugs?
A: R&D of orphan drugs is a long term commitment, with an increasing availability of treatments over the last decade – for numerous serious, life-threatening rare diseases were previously no therapy existed. This is a very successful development since implementation of the EU regulation for Orphan Medicinal Products. With up to 8,000 rare diseases, and for many with still no treatments, there is still a long way to go.

To read more of this interview or for more information please visit http://www.smi-online.co.uk/2014orphandrugs57.asp (http://www.smi-online.co.uk/2014orphandrugs26.asp)

Benefits of Attending 2014 Orphan Drugs and Rare Diseases Conference:

·         Hear important insights from Ian Hudson, CEO, MHRA on the Early Access to Medicines Initiative and adaptive licensing

·         Focus on enhancing development pathways, with the growth of the commercial pipeline for orphan drugs and rare diseases

·         Assess tools for consideration to gain early market access and enhance patient recruitment

·         Interactive round table discussion led by Dominic Nutt, Director of Communications, The Saatchi Cancer Initiative, M&C Saatchi on creating a culture of innovation in the field of orphan drugs and rare diseases

Key Speakers:

·         Dr Gunter Harms, Market Access & Public Affairs Directore, Shire

·         Bertram Haussle, Chaiman of the Board of Management, IGES Institut

·         Josie Godfrey, Associate Director-Highly Specialised Technologies, NICE

·         Chris Hart, Information Practice Leader, AstraZeneca

·         Anthony Hall, Co-Founder, Findacure Foundation

If you would like to attend this conference please contact Dayo Adejuwon on +44 (0) 207 827 6070 or email dadejuwon@smi-online.co.uk (mailto:amccann@smi-online.co.uk)

Contact
SMi Group Ltd
swatson@smi-online.co.uk
+44 (0) 207 827 6070
End
Source: » Follow
Email:***@smi-online.co.uk Email Verified
Tags:Orphan Drugs, Rare Diseases, Drug Development, Pharmaceutical
Industry:Health
Location:England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
SMi Group Ltd. PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share